Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Do Wall Street Analysts Like Aflac Stock?

Dividend Earnings report AI-generated analysis

πŸ“ˆ Aflac shares have significantly outperformed the broader market, rising 15.3% over the past six months compared to the S&P 500's 2.8% gain.

πŸ’° The company returned $1.1 billion to shareholders via share repurchases and dividends, marking its 44th consecutive year of dividend increases.

πŸ“‰ Q3 earnings showed adjusted EPS falling 2.4% to $2.43 while total revenue dropped 31% year over year to $3.27 billion.

πŸ† Aflac reported an annualized return on average shareholders' equity of 4.1% and an adjusted ROE of 23.7% excluding foreign currency effects.

🎯 CEO Daniel P. Amos highlighted a strategic focus on profitable growth, product innovation, and disciplined capital allocation across the U.S. and Japan.

πŸ“Š Analyst consensus rating is "Hold" with a mean price target of $119.44, while Wells Fargo maintains a "Hold" with a target of $116.

Bullish Signals
  • Aflac shares have significantly outperformed the broader market, rising 15.3% over the past six months compared to the S&P 500's 2.8% gain.
  • The company returned $1.1 billion to shareholders through share repurchases and dividends, marking its 44th consecutive year of dividend increases.
  • Aflac reported an annualized return on average shareholders' equity of 4.1% and an adjusted ROE of 23.7% excluding foreign currency effects.
Risk Factors
  • Q3 earnings showed adjusted EPS falling 2.4% to $2.43 while total revenue dropped 31% year over year to $3.27 billion.
  • The company's earnings surprise history is mixed, having beaten consensus estimates in only one of the last four quarters.
Full Analysis
Aflac Incorporated (AFL) continues to demonstrate strong relative performance against the broader market, with shares rising 15.3% over the past six months compared to the S&P 500's 2.8% gain. The company maintains a significant market capitalization of $62.6 billion and operates as a leading provider of supplemental health and life insurance products in the United States and Japan. Following its Q3 earnings release on November 4, Aflac shares increased by 1%, though financial metrics showed contraction. Adjusted earnings per share fell 2.4% to $2.43, while total revenue dropped 31% year over year to $3.27 billion. Despite the revenue decline, the company reported an annualized return on average shareholders' equity of 4.1% and an adjusted ROE of 23.7% when excluding foreign currency remeasurement. Aflac executed a robust capital return program by distributing $1.1 billion to shareholders through $804 million in share repurchases and $305 million in dividends. This marks the 44th consecutive year of dividend increases, with a quarterly dividend declared at $0.61 per share. CEO Daniel P. Amos emphasized a strategic focus on profitable growth, product innovation, and disciplined capital allocation to address evolving customer needs while balancing investments in business expansion. Wall Street analysts maintain a mixed outlook for Aflac, with a consensus rating of "Hold" based on 17 covers including two "Strong Buy" ratings and four "Strong Sells." The mean price target stands at $119.44, suggesting potential upside from current levels, while Wells Fargo analyst Wesley Carmichael maintains a "Hold" rating with a specific price target of $116.